Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report
2022/08/08 by Peter Malfertheiner, Francis Megraud, Françis Mégraud +19 · 34 citations
Medicine · #Helicobacter pylori-related gastroenterology studies #Gastrointestinal disorders and treatments #Gastric Cancer Management and Outcomes
paper · pdf · doi:10.1136/gutjnl-2022-327745
Abstract
Helicobacter pylori Infection is formally recognised as an infectious disease, an entity that is now included in the International Classification of Diseases 11th Revision. This in principle leads to the recommendation that all infected patients should receive treatment. In the context of the wide clinical spectrum associated with Helicobacter pylori gastritis, specific issues persist and require regular updates for optimised management. The identification of distinct clinical scenarios, proper testing and adoption of effective strategies for prevention of gastric cancer and other complications are addressed. H. pylori treatment is challenged by the continuously rising antibiotic resistance and demands for susceptibility testing with consideration of novel molecular technologies and careful selection of first line and rescue therapies. The role of H. pylori and antibiotic therapies and their impact on the gut microbiota are also considered. Progress made in the management of H. pylori infection is covered in the present sixth edition of the Maastricht/Florence 2021 Consensus Report, key aspects related to the clinical role of H. pylori infection were re-evaluated and updated. Forty-one experts from 29 countries representing a global community, examined the new data related to H. pylori infection in five working groups: (1) indications/associations, (2) diagnosis, (3) treatment, (4) prevention/gastric cancer and (5) H. pylori and the gut microbiota. The results of the individual working groups were presented for a final consensus voting that included all participants. Recommendations are provided on the basis of the best available evidence and relevance to the management of H. pylori infection in various clinical fields.
Citations
Cited by
- Global Prevalence of Helicobacter pylori Infection and Incidence of Gastric Cancer Between 1980 and 2022
- HELicobacter Pylori screening to prevent gastrointestinal bleeding in patients with acute Myocardial Infarction (HELP-MI SWEDEHEART) - Design and rationale of a cluster randomized, crossover, registry-based clinical trial
- International consensus statement on microbiome testing in clinical practice
- Occurrence, cultivability, and virulence of Helicobacter pylori in raw vegetables: Comparison between organic and conventional production
- Targeted detection of Helicobacter pylori resistance to clarithromycin and levofloxacin using single-cell Raman spectroscopy
- AGA Clinical Practice Update on Screening and Surveillance in Individuals at Increased Risk for Gastric Cancer in the United States: Expert Review
- The OLGIMA system for gastric cancer risk assessment. A useful method based on the histological Sydney consensus
- Effectiveness and Safety of First‐Line Non‐Bismuth Quadruple Concomitant Therapy Versus Single‐Capsule Bismuth Quadruple Therapy
- SIMPLE: A One-Pot RPA-Cas12b Method for Single Nucleotide Variations Identification with an Expanded Scope and Clinical Applications
- 2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment. [europepmc]
- Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating Helicobacter pylori infection: A prospective, open-labeled, randomized non-inferiority clinical study. [europepmc]
- A Global Perspective on Gastric Cancer Screening: Which Concepts Are Feasible, and When? [europepmc]
- Helicobacter pylori Infection: Current Status and Future Prospects on Diagnostic, Therapeutic and Control Challenges. [europepmc]
- Potassium-Competitive Acid Blockers: Present and Potential Utility in the Armamentarium for Acid Peptic Disorders. [europepmc]
- Helicobacter pylori infection. [europepmc]
- Standard Bismuth Quadruple Therapy versus Concomitant Therapy for the First-Line Treatment of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. [europepmc]
- Eradicating Helicobacter pylori via 13 C-urea breath screening to prevent gastric cancer in indigenous communities: a population-based study and development of a family index-case method. [europepmc]
- The role of the gut microbiota in gastric cancer: the immunoregulation and immunotherapy. [europepmc]
- Antibiotic Resistance, Susceptibility Testing and Stewardship in Helicobacter pylori Infection. [europepmc]
- Lactobacillus acidophilus NCFM and Lactiplantibacillus plantarum Lp-115 inhibit Helicobacter pylori colonization and gastric inflammation in a murine model. [europepmc]
- Biofilm of Helicobacter pylori : Life Cycle, Features, and Treatment Options. [europepmc]
- Evolving Concepts in Helicobacter pylori Management. [europepmc]
- Helicobacter pylori infection: a dynamic process from diagnosis to treatment. [europepmc]
- Ten-Day Vonoprazan-Amoxicillin Dual Therapy vs Standard 14-Day Bismuth-Based Quadruple Therapy for First-Line Helicobacter pylori Eradication: A Multicenter Randomized Clinical Trial. [europepmc]
- Circulating Proteins as Diagnostic Markers in Gastric Cancer. [europepmc]
- Role of probiotics in managing various human diseases, from oral pathology to cancer and gastrointestinal diseases. [europepmc]
- Helicobacter pylori : A Contemporary Perspective on Pathogenesis, Diagnosis and Treatment Strategies. [europepmc]
- Effects of Helicobacter pylori infection on intestinal microbiota, immunity and colorectal cancer risk. [europepmc]
- Vonoprazan: A Review in Helicobacter pylori Infection. [europepmc]
- Role of compliance in Helicobacter pylori eradication treatment: Results of the European Registry on H. pylori management. [europepmc]
- Simplified Helicobacter pylori therapy for patients with penicillin allergy: a randomised controlled trial of vonoprazan-tetracycline dual therapy. [europepmc]
- Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments. [europepmc]
- Where are we with gastric cancer screening in Europe in 2024? [europepmc]
- Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021: results from the European registry on H. pylori management (Hp-EuReg). [europepmc]
Related